These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 30350792)

  • 1. Persistent B Lymphocyte Depletion After an Ultralow Dose of Rituximab for Pemphigus Vulgaris.
    Lazzarotto A; Ferranti M; Meneguzzo A; Sacco G; Alaibac M
    J Investig Allergol Clin Immunol; 2018 Oct; 28(5):347-348. PubMed ID: 30350792
    [No Abstract]   [Full Text] [Related]  

  • 2. Unexpected B lymphocytes depletion in a patient with pemphigus vulgaris after a single dose of 50 mg rituximab.
    Wang R; Li R; Wang M
    J Dermatol; 2024 Oct; 51(10):e365-e366. PubMed ID: 38775209
    [No Abstract]   [Full Text] [Related]  

  • 3. Rituximab as a dual therapeutic option for pemphigus and primary cutaneous B-cell lymphomas: Two case reports.
    Michelerio A; Novario M; Barruscotti S; Vassallo C
    Dermatol Ther; 2019 Jul; 32(4):e12948. PubMed ID: 31025498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose rituximab as an adjuvant therapy in pemphigus.
    Gupta J; Raval RC; Shah AN; Solanki RB; Patel DD; Shah KB; Badheka AD; Shah KB; Aggarwal NK; Ravishankar V
    Indian J Dermatol Venereol Leprol; 2017; 83(3):317-325. PubMed ID: 28366912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relevance of rituximab therapy in pemphigus vulgaris: analysis of current data and the immunologic basis for its observed responses.
    Feldman RJ; Ahmed AR
    Expert Rev Clin Immunol; 2011 Jul; 7(4):529-41. PubMed ID: 21790294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab in pemphigus.
    Hebert V; Joly P
    Immunotherapy; 2018 Jan; 10(1):27-37. PubMed ID: 29064314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose rituximab and concurrent adjuvant therapy for pemphigus: Protocol and single-centre long-term review of nine patients.
    Robinson AJ; Vu M; Unglik GA; Varigos GA; Scardamaglia L
    Australas J Dermatol; 2018 Feb; 59(1):e47-e52. PubMed ID: 28211049
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab mediates a strong elevation of B-cell-activating factor associated with increased pathogen-specific IgG but not autoantibodies in pemphigus vulgaris.
    Nagel A; Podstawa E; Eickmann M; Müller HH; Hertl M; Eming R
    J Invest Dermatol; 2009 Sep; 129(9):2202-10. PubMed ID: 19282839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modifications of the Transcriptomic Profile of Autoreactive B Cells From Pemphigus Patients After Treatment With Rituximab or a Standard Corticosteroid Regimen.
    Hébert V; Petit M; Maho-Vaillant M; Golinski ML; Riou G; Derambure C; Boyer O; Joly P; Calbo S
    Front Immunol; 2019; 10():1794. PubMed ID: 31440235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of immunological parameters in patients with pemphigus vulgaris following rituximab and IVIG therapy.
    Feldman RJ; Christen WG; Ahmed AR
    Br J Dermatol; 2012 Mar; 166(3):511-7. PubMed ID: 21967407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab treatment in pemphigus vulgaris: effect on circulating Tregs.
    El-Zawahry B; Bassiouny D; Hegazy R; Gawdat H; Shalaby S; Khorshied M; Saleh MA
    Arch Dermatol Res; 2017 Sep; 309(7):551-556. PubMed ID: 28631092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and immunological outcomes of high- and low-dose rituximab treatments in patients with pemphigus: a randomized, comparative, observer-blinded study.
    Kanwar AJ; Vinay K; Sawatkar GU; Dogra S; Minz RW; Shear NH; Koga H; Ishii N; Hashimoto T
    Br J Dermatol; 2014 Jun; 170(6):1341-9. PubMed ID: 24640990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Commentary regarding clinical and immunological outcomes of high- and low-dose rituximab treatments in patients with pemphigus: a randomized, comparative, observer-blinded study.
    Yancey KB
    Dermatol Ther; 2015; 28(3):174-5. PubMed ID: 25640417
    [No Abstract]   [Full Text] [Related]  

  • 14. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus.
    Arin MJ; Engert A; Krieg T; Hunzelmann N
    Br J Dermatol; 2005 Sep; 153(3):620-5. PubMed ID: 16120153
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin.
    Ahmed AR; Spigelman Z; Cavacini LA; Posner MR
    N Engl J Med; 2006 Oct; 355(17):1772-9. PubMed ID: 17065638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab immunotherapy in pemphigus: therapeutic effects beyond B-cell depletion.
    Zambruno G; Borradori L
    J Invest Dermatol; 2008 Dec; 128(12):2745-7. PubMed ID: 18997839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cluster of differentiation 19 + B-lymphocyte cell as a predictor of relapse in pemphigus vulgaris.
    Patel NH; Padhiyar JK; Raval RC
    Indian J Dermatol Venereol Leprol; 2021; 87(2):237-238. PubMed ID: 33769759
    [No Abstract]   [Full Text] [Related]  

  • 18. Low-dose rituximab is effective in pemphigus.
    Horváth B; Huizinga J; Pas HH; Mulder AB; Jonkman MF
    Br J Dermatol; 2012 Feb; 166(2):405-12. PubMed ID: 21967609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cutaneous B cell pseudolymphoma treated with rituximab and methotrexate.
    Besch-Stokes JG; Patel MH; Brumfiel CM; Costello CM; Rule W; Rosenthal A; Pittelkow MR; DiCaudo DJ; Mangold AR
    Dermatol Online J; 2021 Sep; 27(9):. PubMed ID: 34755980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab exerts a dual effect in pemphigus vulgaris.
    Eming R; Nagel A; Wolff-Franke S; Podstawa E; Debus D; Hertl M
    J Invest Dermatol; 2008 Dec; 128(12):2850-8. PubMed ID: 18563178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.